

**REMARKS**

Applicants respectfully request reconsideration of the claims. Claims 1 and 6-16 are pending. Applicants respectfully request reconsideration and withdrawal of the pending rejection under the judicial doctrine of obviousness-type double patenting.

**Obviousness-Type Double Patenting Rejections**

The Examiner rejects the claims under the judicial doctrine of obviousness-type double patenting in view of claims 1-7 and 14-16 of U.S. Patent No. 6,043,259 in view of Goodman & Gilman's **The Pharmacological Basis of Disease** (Hardman et al., 9th ed.). While not acquiescing to the rejection and in order to expedite prosecution, Applicants submit a terminal disclaimer to U.S. Patent No. 6,043,259 to obviate the obviousness-type double patenting rejection.

In view of the foregoing, Applicants respectfully request removal of the obviousness-type double patenting rejections.


**Summary**

In view of the above amendments and remarks, Applicant respectfully requests a Notice of Allowance. If the Examiner believes a telephone conference would advance the prosecution of this application, the Examiner is invited to telephone the undersigned at the below-listed telephone number.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: June 27, 2006

  
Brian R. Dorn, Ph.D.  
Reg. No. 57,395  
BRD:RAD:sab

**23552**

PATENT TRADEMARK OFFICE